Loading…
← CockpitCompetitor Analysis › SYMBIOTEC.NS Symbiotec Pharmalab LimitedOpen in the cockpit ↗

Symbiotec Pharmalab LimitedSYMBIOTEC.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Mkt cap
$1.12B
US dollars, full cap
Free float
70%
of shares outstanding
$/day
$14.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 19.5%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · INR₹1,621
1D+1.3%
1W+5.4%
1M+30.9%
3Mn/a
6Mn/a
YTDn/a
1Yn/a
ATR %5.2%
52w lowhigh2.6% off high

What Symbiotec Pharmalab does

No business profile yet.

Symbiotec Pharmalab at a glance

Size Symbiotec Pharmalab (SYMBIOTEC.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.12B, the 567th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,621 on 18 Nov 2026.

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Symbiotec Pharmalab financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/an/a₹7.36B₹7.00B₹5.51B
Revenue growth——+5%+27%—
Gross profitn/an/a₹2.04B₹1.73B₹788M
EBITDAn/an/a₹1.91B₹1.60B₹592M
Net incomen/an/a₹968M₹1.00B₹235M
Free cash flown/an/a-₹2.75B-₹290M-₹1.61B
Capital expendituren/an/a₹3.08B₹2.10B₹2.24B
Total debt₹3.36Bn/a₹5.44B₹2.51B₹2.20B

Quarterly statements and history in the cockpit →

Symbiotec Pharmalab competitors and peer comparison

How Symbiotec Pharmalab compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Symbiotec Pharmalab against its 20 peers (data as of 18 Nov 2026)
MeasureSYMBIOTEC.NSPeer medianRank in peer set
1-month return+30.9%-2.3%highest of 21
Distance from 52-week high-2.6%-33.1%highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Symbiotec Pharmalab SYMBIOTEC.NSIndia$1.12Bn/an/an/an/an/an/a
Viyash Scientific VIYASH.NSIndia$1.11B+3%+124%13%2.9×36.3%+20.4%
GC Biopharma 006280.KSSouth Korea$1.12B-10%-3%4%1.2×n/an/a
ST Pharm 237690.KSSouth Korea$1.11B-51%+26%18%3.5×4.2%+21.7%
Tianjin Ringpu Bio-technology 300119.SZChina$1.11B-7%-9%11%2.3×4.9%+11.3%
Vetoquinol VETO.PAFrance$1.10B+19%-1%15%1.5×-3.6%+4.2%
Cosmo CMHC.SWSwitzerland$1.13B-30%-45%-13%8.2×n/an/a
Changzhou Qianhong Bio-Pharma 002550.SZChina$1.14B-12%-2%15%4.2×3.4%-1.2%
PYC Therapeutics PYC.AXAustralia$1.09B+29%n/an/an/an/an/a
Kissei Pharmaceutical 4547.TJapan$1.14B+3%+6%6%1.4×n/an/a
MedinCell MEDCL.PAFrance$1.09B+4%-23%-131%49.6×n/an/a
North China Pharmaceutical 600812.SSChina$1.08B-12%-21%5%2.4×1.0%-4.2%
Omeros OMERUnited States$1.08B+24%n/a-56%17.3×n/an/a
Jiuzhitang 000989.SZChina$1.16B-7%+46%19%2.6×-4.0%-9.0%
Ascentage Pharma Group International 6855.HKHong Kong$1.18B-34%+70%-220%13.2×n/an/a
Nektar Therapeutics NKTRUnited States$1.18B-50%-17%-304%13.3×n/an/a
Chongqing Genrix Biopharmaceutical 688443.SSChina$1.18B-22%+256%-27%8.6×n/an/a
Everest Medicines 1952.HKHong Kong$1.05B-20%+193%-5%3.0×n/an/a
Shenzhen Chipscreen Biosciences 688321.SSChina$1.18B-38%+27%12%7.6×n/an/a
Blue Jet Healthcare BLUEJET.NSIndia$1.05B+19%-7%28%8.1×40.8%+13.8%
Shandong Lukang Pharmaceutical 600789.SSChina$1.05B-18%-7%3%1.5×2.5%+6.5%

Questions

Which companies are Symbiotec Pharmalab's closest peers?
The cockpit's peer set: Viyash Scientific (VIYASH.NS), GC Biopharma (006280.KS), ST Pharm (237690.KS), Tianjin Ringpu Bio-technology (300119.SZ), Vetoquinol (VETO.PA), Cosmo (CMHC.SW), Changzhou Qianhong Bio-Pharma (002550.SZ), PYC Therapeutics (PYC.AX).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.